海正藥業(600267.SH)控股子公司雲生公司啟動預重整
格隆匯10月12日丨海正藥業(600267.SH)公佈,2020年10月9日,雲南生物製藥有限公司(以下簡稱“雲生公司”)收到雲南省昆明市中級人民法院《決定書》,為降低重整成本、提高重整成功率,有效識別雲生公司重整價值及重整可行性,雲南省昆明市中級人民法院依雲生公司申請,決定對其啟動預重整。按照《最高人民法院關於審理企業破產案件指定管理人的規定》第二十一條之規定,法院指定雲南生物製藥有限公司清算組擔任雲南生物製藥有限公司預重整期間的臨時管理人。預重整期間,臨時管理人將依法履行法定職責,依法推進預重整期間各項工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.